---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-095167"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2025-07-11T23:59:59+00:00"
generated_at: "2026-05-18T06:54:48.508263+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Karyopharm cuts workforce 20%, explores strategic alternatives including sale

## Summary
- Reducing workforce by ~20% as part of ongoing expense management; one-time costs immaterial.
- Board evaluating financing, merger/sale, restructuring, or debt refinancing; no deal yet.
- Engaged with potential investors under confidentiality; discussions did not result in a transaction.
- Committed to Phase 3 trials in myelofibrosis and endometrial cancer.

## SEC filing metadata
- accession: 0000950170-25-095167
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2025-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000095017025095167/0000950170-25-095167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000095017025095167/kpti-20250711.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-095167
- JSON: https://secwatch.observer/filing/0000950170-25-095167.json
- Plain text: https://secwatch.observer/filing/0000950170-25-095167.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.